News from ptc therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 23, 2023, 16:07 ET PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The...

May 23, 2023, 16:05 ET PTC Therapeutics Announces Strategic Pipeline Prioritization

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a...

May 18, 2023, 08:59 ET PTC Therapeutics anuncia que o estudo clínico APHENITY atingiu o desfecho primário com sepiapterina em pacientes com Fenilcetonúria (PKU)

May 18, 2023, 08:56 ET PTC Therapeutics anuncia que el ensayo APHENITY logró el criterio de valoración primario con sepiapterina en pacientes con PKU

May 17, 2023, 13:08 ET PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical...

May 17, 2023, 07:00 ET PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical...

Apr 28, 2023, 08:00 ET PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2023, the company approved non-statutory stock options to purchase an...

Apr 27, 2023, 16:01 ET PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2023. "We are...

Apr 13, 2023, 08:00 ET PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial ...

Mar 28, 2023, 08:00 ET PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023, the company approved non-statutory stock options to purchase an...

Feb 21, 2023, 16:05 ET PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...

Feb 07, 2023, 22:15 ET PTC Therapeutics lança o 9º programa anual de prêmios STRIVE™ para financiar iniciativas que beneficiam a comunidade de distrofia muscular de Duchenne

Feb 07, 2023, 21:58 ET PTC Therapeutics lanza el noveno programa anual de premios STRIVE™ para financiar iniciativas que beneficien a la comunidad con distrofia muscular de Duchenne

Feb 07, 2023, 16:30 ET PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year ...

Jan 22, 2023, 23:21 ET NICE recomenda reembolso para Translarna™

Jan 20, 2023, 07:35 ET NICE recomienda el reembolso de Translarna™

Jan 19, 2023, 08:00 ET NICE Recommends Reimbursement for Translarna™

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation ...

Jan 09, 2023, 09:15 ET PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare...